Shift Bioscience key facts
- Operator of a biotechnology company intended to develop simulation-guided cell rejuvenation therapies to address the diseases of aging.
- Shift Bioscience’s last known valuation is $30.5M.
- It has raised $17.5M; the latest was Seed Round ($10.9M) in Jun 2024.
- Notable investors include F-Prime Capital, Boost VC, BGF (Financial Services), Meltwind Advisory, Jonathan Milner — 13 tracked in total.
- Status: Privately Held (backing).
Who backs Shift Bioscience
13+- ·The complete investor list: 13 names
- ·Watch Shift Bioscience: the Monday email on marks, rounds and moves
Shift Bioscience funding rounds
No funding rounds for Shift Bioscience are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Shift Bioscience valuation
Shift Bioscience's last known valuation is $30.5 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
Shift Bioscience investors
13 investors are on record for Shift Bioscience, including F-Prime Capital, Boost VC, BGF (Financial Services) and Meltwind Advisory.
About Shift Bioscience
Operator of a biotechnology company intended to develop simulation-guided cell rejuvenation therapies to address the diseases of aging. The company utilizes simulation-guided techniques to discover gene-based interventions that rejuvenate cells without altering stem cell identity by identifying interventions that reverse epigenetic age markers, including single-gene therapies, enabling healthcare professionals to promote healthy aging.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2017
- Employees
- 25
- Website
- shiftbioscience.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Shift Bioscience’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.